# BOSTON SCIENTIFIC CORP (BSX) — merger/definitive [pending]
Source: sec.gov · situation sit_c349ea559afae57baa31 · public 8242748294157550005 · retrieved 2026-08-20T13:45:21.995Z

## Overview
The medical device markets in which we participate are highly competitive.

BOSTON SCIENTIFIC CORP announced a merger in a Form 425 filing.

## Terms
- Counterparty: Guidant Corporation · Deal value: $27.00B · Consideration: mixed · Premium: 13.0% · Stake: 36% · Price/share: $80

## Key dates
- Announced 2006-01-09 · Vote 2006-03-31 · Expiry 2006-04-13 · Expected close 2006-04-07

## Timeline
- 2006-01-09 · 425 (0001104659-06-001147): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation develops and manufactures surgical and medical instruments and apparatus, including cardiovascular devices, endosurgery, and neuromodulation products.* Boston Scientific submitted a definitive offer to acquire all outstanding shares of Guidant Corporation for a combination of cash and stock worth $72 per Guidant share, totaling $25 billion. The offer was approved by Boston Scientific's Board of Directors and submitted for review by Guidant's Board. Guidant had previously entered into an agreement with Johnson & Johnson, which would have an opportunity to respond under its contract with Guidant. Boston Scientific also announced a binding definitive agreement with Abbott Laboratories, under which Abbott will purchase Guidant's vascular intervention and endovascular businesses upon completion of Boston Scientific's proposed acquisition, with Boston Scientific sharing rights to Guidant's drug-eluting stent portfolio with Abbott.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-001147.txt
- 2006-01-09 · 425 (0001104659-06-001162): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device company specializing in cardiovascular devices, including drug-eluting stents, pacemakers, implantable cardioverter-defibrillators, and other interventional vascular and neuromodulation products.* Boston Scientific Corporation made a definitive offer to acquire Guidant Corporation for $72.00 per share in an all-cash and stock combination (50% cash, 50% stock, representing 469 million shares). The offer represents a 12% premium to Johnson & Johnson's revised offer of $64.11 per share. The transaction is subject to Boston Scientific and Guidant shareholder votes and antitrust clearances, with expected closing by the end of Q1 2006. The offer includes a collar of ±10% ($23.62–$28.86) on Boston Scientific's share price, and pro forma ownership would be 64% for BSC shareholders and 36% for Guidant shareholders.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-001162.txt
- 2006-01-09 · 425 (0001104659-06-001132): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation submitted a definitive merger offer to acquire all outstanding shares of Guidant Corporation for $72 per share in a combination of cash and stock, totaling $25 billion in aggregate. Each Guidant share would be exchanged for $36 in cash and $36 in Boston Scientific common stock, based on the average closing price of Boston Scientific stock during the 20 consecutive trading days ending three days before Guidant's shareholder meeting. The offer includes a collar mechanism: if Boston Scientific's average closing price falls below $23.62, Guidant shareholders receive 1.5241 Boston Scientific shares per Guidant share; if it exceeds $28.86, they receive 1.2474 shares per Guidant share. The offer represents approximately a 12% premium over Johnson & Johnson's revised merger proposal and is not subject to any financing condition.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-001132.txt
- 2006-01-09 · 425 (0001104659-06-001190): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties, including coronary stent systems.* Boston Scientific Corporation announced preliminary 2005 sales results and disclosed in forward-looking statements that it is pursuing a proposed business combination with Guidant Corporation. The filing indicates that Boston Scientific and Guidant have not yet entered into a definitive agreement, and that regulatory approvals and consummation of the transaction remain uncertain. No transaction value, consideration type, or expected closing date has been disclosed at this stage.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-001190.txt
- 2006-01-10 · 425 (0001104659-06-001444): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation develops and manufactures cardiovascular medical devices, including drug-eluting stents (DES) and other interventional cardiology products.* Boston Scientific submitted a definitive offer to acquire Guidant for $72 per share in an all-cash-and-stock combination ($36 cash and $36 in Boston Scientific stock), valuing the transaction at approximately $25 billion. The offer includes a 10% symmetrical collar on the stock portion based on Boston Scientific's closing share price of $26.24, with Guidant shareholders receiving between 1.2474 and 1.5241 Boston Scientific shares per Guidant share depending on Boston Scientific's average stock price during the 20 consecutive trading days ending three days prior to the Guidant shareholder meeting. Concurrently, Boston Scientific executed a binding agreement with Abbott to divest Guidant's vascular intervention and endovascular businesses for $4.3 billion in total consideration, consisting of $3.8 billion upfront cash at closing, two $250 million milestone payments upon FDA approvals of an everolimus-based DES product in the U.S. and Japan (within ten years), and a five-year $700 million subordinated loan at 5.25% interest. The transaction is subject to Hart-Scott-Rodino and European Union merger control clearance, as well as shareholder approval from both companies, with expected closing in the first quarter of 2006.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-001444.txt
- 2006-01-12 · 425 (0001104659-06-001777): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation issued a statement on January 11, 2006, asserting that its $72 per share offer to acquire Guidant Corporation is superior to Johnson & Johnson's amended agreement of $68.06 per share in cash and stock. Boston Scientific stated that its discussions with Guidant are ongoing and that it intends to vigorously pursue the transaction to completion.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-001777.txt
- 2006-01-13 · 425 (0001104659-06-002022): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation announced an improved definitive offer to acquire Guidant Corporation for $73 per share, consisting of $36.50 in cash and $36.50 in Boston Scientific common stock, subject to a collar. The amended offer, which addresses all outstanding issues raised by Guidant's Board including antitrust concerns and certainty of value, expires at 4:00 p.m. ET on January 13, 2006, unless Guidant's Board declares it superior to Johnson & Johnson's competing $67.92 per share transaction. If the transaction does not close by March 31, 2006, the $73 per share price will be increased by $0.012 in cash for each day between April 1, 2006, and the closing date (representing an annual interest rate of 6 percent). The offer is not subject to any financing condition, and Boston Scientific has agreed to divest all overlapping assets if required to address antitrust concerns.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-002022.txt
- 2006-01-13 · 425 (0001104659-06-002038): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation develops, manufactures and markets medical devices including cardiovascular, rhythm management, endoscopy, oncology and other medical device products.* Boston Scientific Corporation submitted a revised definitive offer on January 12, 2006 to acquire Guidant Corporation at $73 per share, increased from the prior offer of $72 per share. The consideration consists of $36.50 in cash and $36.50 in Boston Scientific common stock per Guidant share, with the stock portion based on the average closing price of Boston Scientific stock during the 20 trading days ending three days before Guidant's shareholder meeting (subject to a collar of 1.2647 to 1.5453 shares). If closing does not occur by March 31, 2006, Guidant shareholders receive an additional $0.0120 per share per day (6% annual interest). Boston Scientific's board unanimously approved the offer, and holders of approximately 30% of Boston Scientific shares agreed to vote in favor. The offer provides Guidant shareholders approximately $1.8 billion more than Johnson & Johnson's competing bid and represents a 7.5% premium over J&J's revised offer. The offer remains open until 4:00 pm on January 24, 2006, provided it automatically terminates at 4:00 pm on January 13, 2006 unless Guidant's board determines the offer constitutes a superior proposal and notifies J&J of its intention to terminate their merger agreement.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-002038.txt
- 2006-01-17 · 425 (0001104659-06-002259): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation announced a revised acquisition offer for Guidant Corporation on January 17, 2006, at $80 per share in aggregate consideration of approximately $27 billion. The offer consists of $42.00 in cash and $38.00 in Boston Scientific common stock per Guidant share, subject to a collar with a floor of $22.62 and ceiling of $28.86. The offer includes an expanded collar providing additional certainty of value and interest payments at 6% annually if closing does not occur by March 31, 2006. Boston Scientific has amended its agreement with Abbott Laboratories to increase the purchase price for divested Guidant assets from $3.8 billion to $4.1 billion and increase the loan commitment from $700 million to $900 million, with Abbott also agreeing to purchase $1.4 billion of Boston Scientific common stock (approximately 56 million shares) contingent on closing. The offer was delivered via signed merger agreement and was set to expire at 5:00 p.m. ET on January 17, 2006 unless Guidant's Board declared it superior to Johnson & Johnson's $71 per share offer, in which case it would remain open until January 25, 2006.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-002259.txt
- 2006-01-18 · 425 (0001104659-06-002666): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device company specializing in cardiovascular devices and surgical instruments.* Boston Scientific Corporation announced a superior offer to acquire Guidant Corporation for $80.00 per share in cash and stock, representing a 13% premium to Johnson & Johnson's revised offer of $71.00 per share. The consideration consists of 52.5% cash ($42.00 per share) and 47.5% stock (1.5079 BSC shares per Guidant share, based on BSC's closing price of $25.20 on January 13, 2006). The transaction is subject to a collar of $22.62 to $28.86 per BSC share, with pro forma ownership of 63% for BSC shareholders and 37% for Guidant shareholders. The transaction requires approval from both BSC and Guidant shareholders and antitrust clearances, with expected closing in Q1 2006.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-002666.txt
- 2006-01-18 · 425 (0001104659-06-002561): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Guidant Corporation's Board of Directors determined that Boston Scientific Corporation's definitive offer is superior to Johnson & Johnson's agreement for the acquisition of Guidant. Boston Scientific issued a statement acknowledging the board's decision and expressing its intention to work with Guidant to complete the transaction. The filing does not disclose the transaction value, per-share price, or expected closing date.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-002561.txt
- 2006-01-25 · 425 (0001104659-06-003775): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation and Guidant Corporation entered into a merger agreement dated January 25, 2006, under which Boston Scientific will acquire all outstanding shares of Guidant common stock for a combination of cash and stock worth $80 per Guidant share, or approximately $27 billion in aggregate. Each share of Guidant common stock will be exchanged for $42.00 in cash and $38.00 in Boston Scientific common stock (based on the average closing price of Boston Scientific common stock during the 20 consecutive trading day period ending three days prior to closing). Guidant shareholders will own approximately 36 percent of the combined company. The transaction is subject to customary closing conditions, including Hart-Scott-Rodino and European Union merger control clearances, as well as shareholder approval of both companies. Boston Scientific expects to complete the transaction by the end of the first quarter of 2006.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-003775.txt
- 2006-02-07 · 425 (0001104659-06-006636): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device manufacturer specializing in cardiovascular, endosurgery, and neuromodulation products, with 2005 worldwide sales of $6.283 billion.* Boston Scientific Corporation filed a Form 425 prospectus communication on February 7, 2006, regarding its proposed acquisition of Guidant Corporation. The filing contains presentation materials and forward-looking statements about the business combination. The transaction is subject to regulatory approvals and customary closing conditions. Boston Scientific and Guidant have filed a preliminary prospectus/proxy statement with the SEC in connection with the proposed transaction.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-006636.txt
- 2006-02-08 · 425 (0001104659-06-006968): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device manufacturer specializing in drug-eluting stents (TAXUS®), cardiovascular devices, endosurgery, oncology, endoscopy, and urology products; in 2005 it achieved $6.3 billion in worldwide sales with 12% growth.* Boston Scientific Corporation announced its acquisition of Guidant Corporation at $80 per share in an all-stock transaction. The company filed its Hart-Scott-Rodino antitrust filing and S-4 registration statement with the SEC on February 7, 2006. Management expects to obtain required regulatory approvals from the FTC and European Commission by the end of Q1 2006, with shareholder meetings planned by the end of March 2006. The combined entity is projected to generate approximately $10 billion in 2007 revenues with 12% compound annual revenue growth and 20% adjusted EPS growth over five years.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-006968.txt
- 2006-02-08 · 425 (0001104659-06-007025): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device company that develops and markets cardiovascular, endosurgery, and neuromodulation products, including the market-leading TAXUS stent system.* Boston Scientific Corporation is acquiring Guidant Corporation in a merger transaction. The primary goal is a successful and timely close by March 31, 2006. The transaction requires clearance from U.S. and European regulators, as well as approval from Boston Scientific and Guidant shareholders. As part of the transaction, Guidant's vascular intervention and endovascular businesses will be transferred to Abbott. The combined organization will integrate Guidant's cardiac rhythm management business as a new group within Boston Scientific, and the cardiac surgery business will become part of Boston Scientific's Cardiovascular group.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-007025.txt
- 2006-02-08 · 425 (0001104659-06-007032): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation develops and manufactures cardiovascular medical devices and other medical technologies; founded in 1979, it has grown to over 18,000 employees and more than $6 billion in sales.* Boston Scientific Corporation signed an agreement on January 25, 2006 to acquire Guidant Corporation, creating a global leader in cardiovascular medical devices and a broad medical technology company. As part of the transaction structure, Boston Scientific agreed that Abbott will acquire Guidant's vascular intervention and endovascular businesses, with Boston Scientific and Abbott sharing rights to Guidant's drug-eluting stent program. The companies expect to close the transaction by the end of March 2006.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-007032.txt
- 2006-02-23 · 425 (0001104659-06-011665): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation announced on February 23, 2006 that it has filed notification with the European Commission of its intention to acquire all outstanding shares of Guidant Corporation. Under a merger agreement entered into on January 25, 2006, Boston Scientific will acquire Guidant for a combination of cash and stock worth $80 per Guidant share, or approximately $27 billion in aggregate. Boston Scientific has also entered into an agreement with Abbott Laboratories under which Abbott will acquire Guidant's vascular intervention and endovascular businesses while sharing rights to Guidant's drug-eluting stent program with Boston Scientific.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-011665.txt
- 2006-03-03 · 425 (0001104659-06-013795): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation agreed to acquire all outstanding shares of Guidant Corporation for a combination of cash and stock worth $80 per Guidant share, totaling approximately $27 billion in aggregate consideration. Guidant shareholders will also receive an additional $0.0132 in cash per share for each day from April 1, 2006 through the merger closing date. The merger is subject to customary closing conditions, including Hart-Scott-Rodino antitrust clearance and European Union merger control approval, as well as shareholder approval. Both companies' shareholders are scheduled to vote on the proposed merger on March 31, 2006, and Boston Scientific expects the transaction to close during the week of April 3, 2006.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-013795.txt
- 2006-03-03 · 425 (0001104659-06-013885): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a surgical and medical instruments and apparatus manufacturer.* Boston Scientific Corporation announced that the U.S. Securities and Exchange Commission declared its Form S-4 registration statement effective on March 2, 2006. The company stated that shareholder meetings for both Guidant and Boston Scientific have been scheduled for March 31, 2006, to approve the proposed merger transaction. Boston Scientific expects to close the merger during the week of April 3, 2006, pending remaining regulatory approvals from the U.S. Federal Trade Commission and the European Commission.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-013885.txt
- 2006-03-08 · 425 (0001104659-06-015037): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device company with a diverse portfolio of products across interventional cardiology, endoscopy, peripheral, urology, neurovascular, oncology, neuromodulation, electrophysiology, and vascular surgery, with 90%+ of sales from market-leading products.* Boston Scientific Corporation announced a proposed business combination with Guidant Corporation. The transaction is valued at $27.5 billion in purchase price plus $0.9 billion in transaction expenses, for a total transaction value of $28.4 billion. Financing sources include $13.0 billion in equity to Guidant shareholders, $5.1 billion from Abbott (net of tax), $7.1 billion in bank loans, and $3.2 billion in available cash. Boston Scientific and Guidant shareholders are scheduled to vote on the transaction on March 31, with the transaction expected to close the week of April 3.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-015037.txt
- 2006-03-08 · 425 (0001104659-06-015046): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device company that develops, designs, and sells interventional cardiology devices, including drug-eluting stents (TAXUS), endoscopy equipment, and other cardiovascular and surgical products; it is the market leader in interventional cardiology with over 45% market share and generated $6.3 billion in sales in 2005.* Boston Scientific Corporation is acquiring Guidant Corporation in a transforming transaction valued at $27 billion. The deal includes Boston Scientific issuing stock to Guidant shareholders, Abbott contributing a net after-tax payment of $5.1 billion (and acquiring Guidant's vascular intervention business), bank loans of $7.1 billion, and combined incremental cash of $3.2 billion. The transaction is expected to close in the week of April 3, 2006, subject to shareholder approval at a joint meeting scheduled for March 31, 2006, at an offer price of $80 per share. The acquisition combines Boston Scientific's number-one position in interventional cardiology with Guidant's cardiac rhythm management (CRM) business, creating a diversified cardiovascular platform with approximately 35% of the $19 billion cardiovascular market.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-015046.txt
- 2006-03-08 · 425 (0001104659-06-015067): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a surgical and medical instruments and apparatus manufacturer.* Boston Scientific Corporation voluntarily withdrew and re-filed its Hart-Scott-Rodino (HSR) antitrust notification in connection with its pending acquisition of Guidant Corporation. The companies signed their agreement and plan of merger on January 25, 2006. Boston Scientific expects the merger to close during the week of April 3, 2006.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-015067.txt
- 2006-03-10 · 425 (0001104659-06-015874): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation announced plans to acquire all outstanding shares of Guidant Corporation for a combination of cash and stock worth $80 per Guidant share, representing approximately $27 billion in aggregate consideration. The merger agreement was entered into on January 25, 2006. The acquisition is expected to close during the first week of April 2006. Upon closing, Guidant's Cardiac Rhythm Management (CRM) operations will become part of Boston Scientific's new CRM Group, with a leadership team appointed to oversee the integration.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-015874.txt
- 2006-03-13 · 425 (0001104659-06-016032): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device company with a portfolio of 74 product divisions across 270 categories including interventional cardiology, endoscopy, peripheral vascular, urology, neurovascular, oncology, neuromodulation, electrophysiology, and vascular surgery, with over 90% of sales from market-leading products.* Boston Scientific Corporation announced a proposed business combination with Guidant Corporation. The transaction is valued at $27.5 billion in purchase price plus $0.9 billion in transaction expenses, for a total transaction value of $28.4 billion. The consideration consists of $13.0 billion in equity to Guidant shareholders, $5.1 billion from Abbott (net of tax), $7.1 billion in bank loans, and $3.2 billion in available cash. Boston Scientific and Guidant shareholders are scheduled to vote on the transaction on March 31, with closing expected the week of April 3. The companies have obtained committed financing, completed confirmatory due diligence, executed a definitive merger agreement, and filed required regulatory documents including HSR and EU antitrust filings.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-016032.txt
- 2006-03-13 · 425 (0001104659-06-016035): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a medical device company with $6.3 billion in 2005 sales, 90% from number-one market share positions, with 40% of revenue from TAXUS drug-eluting stents and leading positions in interventional cardiology and other device markets.* Boston Scientific Corporation is acquiring Guidant Corporation in a transforming transaction valued at approximately $27 billion (including ~$1 billion in transaction expenses and a $700 million penalty for reaching a definitive agreement). The acquisition was announced December 5, 2005, with a definitive agreement signed January 25, 2006. Boston Scientific expects to close the transaction in the week of April 3, 2006. The deal will be financed through approximately $13 billion in Boston Scientific equity, $5.1 billion in after-tax proceeds from Abbott's purchase of Guidant's Vascular Interventions Group, $7 billion in bank loans, and available cash. Post-closing, Abbott will acquire Guidant's Vascular Interventions business, while Boston Scientific will acquire Guidant's cardiac rhythm management (CRM) and cardiac surgery operations.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-016035.txt
- 2006-03-15 · 425 (0001104659-06-016590): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation develops and manufactures drug-eluting stents, including the TAXUS platform, along with cardiovascular and peripheral vascular intervention devices.* Boston Scientific Corporation is acquiring Guidant Corporation in a transaction expected to close in the first week of April 2006. The deal is progressing smoothly according to plan, with Boston Scientific managing a complex separation strategy that includes divesting Guidant's vascular intervention business. The transaction is expected to diversify Boston Scientific and accelerate its overall growth platform, with integration planning underway for the combined company.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-016590.txt
- 2006-03-15 · 425 (0001104659-06-016581): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation develops and markets medical devices including drug-eluting stents (TAXUS), interventional cardiology products, and peripheral vascular devices.* This Form 425 filing contains presentation materials from Boston Scientific Corporation regarding the proposed business combination with Guidant Corporation. The materials were presented at an Analyst Meeting at the American College of Cardiology (ACC) on March 13, 2006, and made available on Boston Scientific's website. The presentation discusses Boston Scientific's cardiovascular business, TAXUS drug-eluting stent program, and pipeline products, with references to the pending Guidant transaction.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-016581.txt
- 2006-03-20 · 425 (0001104659-06-017901): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation announced it will acquire all outstanding shares of Guidant Corporation for a combination of cash and stock worth $80 per Guidant share, or approximately $27 billion in aggregate, pursuant to a merger agreement entered into on January 25, 2006. Guidant shareholders will receive an additional $0.0132 in cash per Guidant share for each day from April 1, 2006 through the closing date. Boston Scientific expects to close the transaction during the first week of April 2006. Boston Scientific has also entered into an agreement with Abbott to divest Guidant's vascular intervention and endovascular businesses.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-017901.txt
- 2006-03-24 · 425 (0001104659-06-019011): 425 - BOSTON SCIENTIFIC CORP — *Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.* Boston Scientific Corporation announced it has made antitrust commitments to the European Commission as part of its review of Boston Scientific's merger with Guidant Corporation. Under the merger agreement announced January 25, 2006, Boston Scientific will acquire all outstanding shares of Guidant for a combination of cash and stock worth $80 per Guidant share, or approximately $27 billion in aggregate. Guidant shareholders will receive an additional $0.0132 in cash per Guidant share for each day beginning April 1, 2006 through the closing date. The European Commission review, extended by the commitments from the typical five-week period to up to seven weeks, will formally conclude no later than April 13, 2006, though Boston Scientific's goal is to close the transaction during the first week of April.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-06-019011.txt
- 2026-04-22 · 425 (0001104659-26-046912): 425 - BOSTON SCIENTIFIC CORP — *The medical device markets in which we participate are highly competitive.* BOSTON SCIENTIFIC CORP announced a merger in a Form 425 filing.
  https://www.sec.gov/Archives/edgar/data/885725/0001104659-26-046912.txt

## Citations
- 0001104659-06-001147 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906001147
- 0001104659-06-001162 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906001162
- 0001104659-06-001132 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906001132
- 0001104659-06-001190 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906001190
- 0001104659-06-001444 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906001444
- 0001104659-06-001777 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906001777
- 0001104659-06-002022 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906002022
- 0001104659-06-002038 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906002038
- 0001104659-06-002259 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906002259
- 0001104659-06-002666 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906002666
- 0001104659-06-002561 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906002561
- 0001104659-06-003775 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906003775
- 0001104659-06-006636 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906006636
- 0001104659-06-006968 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906006968
- 0001104659-06-007025 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906007025
- 0001104659-06-007032 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906007032
- 0001104659-06-011665 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906011665
- 0001104659-06-013795 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906013795
- 0001104659-06-013885 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906013885
- 0001104659-06-015037 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906015037
- 0001104659-06-015046 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906015046
- 0001104659-06-015067 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906015067
- 0001104659-06-015874 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906015874
- 0001104659-06-016032 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906016032
- 0001104659-06-016035 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906016035
- 0001104659-06-016590 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906016590
- 0001104659-06-016581 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906016581
- 0001104659-06-017901 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906017901
- 0001104659-06-019011 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465906019011
- 0001104659-26-046912 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926046912